Table 1.

Agents currently in clinical trials as treatments for inflammation in diabetic macular edema.

Drug class	Molecule	Administration	Trial number	Trial status
Steroid	Betamethasone microsphere	Posterior sub-Tenon	NCT01411254	Phase 2/3 completed
	Dexamethasone-cyclodextrin	Topical	NCT01523314	Unknown
	Danazol	Oral	NCT02002403	Phase 2 completed
	NOVA63035	Intravitreal	NCT00665106	Phase 1 completed
TNF alpha inhibitor	Infliximab	Intravitreal	NCT00959725	Unknown
Tie-2 activator	AKB-9778	Subcutaneous	NCT02050828	Phase 2 completed
IGF-1 antagonist	Teprotumumab	Intravenous	NCT02103283	Phase 1 completed
Integrin antagonist	SF0166	Topical	NCT02914613	Phase 1/2 completed
mTOR inhibitor	Sirolimus	Subconjunctival	NCT00711490	Phase 1/2 completed

IGF = insulin-like growth factor; mTOR = mechanistic target of rapamycin; TNF = tumor necrosis factor.